We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The company has two clinical-stage programs and a second program that is discovery-stage and partnered with another company. Lux... Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The company has two clinical-stage programs and a second program that is discovery-stage and partnered with another company. Luxeptinib, its panFMS-like tyrosine kinase 3 / pan-Bruton's tyrosine kinase inhibitor, is enrolling patients in a Phase 1, multicenter, open label, dose-escalation study with expansions to assess the safety, tolerability, PK, and preliminary efficacy of CG-806 in patients with chronic lymphocytic leukemia (CLL/SLL) or non-Hodgkin lymphomas (NHL). HM43239 is an oral potent myeloid kinome inhibitor, targeting a constellation of kinases operative in myeloid malignancies. Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.02 | -1.61290322581 | 1.24 | 1.285 | 1.15 | 44999 | 1.21300876 | CS |
4 | -0.5 | -29.0697674419 | 1.72 | 1.7203 | 1.15 | 71736 | 1.39509136 | CS |
12 | -0.78 | -39 | 2 | 2.2 | 1.15 | 79205 | 1.67161529 | CS |
26 | -1.38 | -53.0769230769 | 2.6 | 3.32 | 1.15 | 76136 | 2.00907086 | CS |
52 | -6.28 | -83.7333333333 | 7.5 | 8.7 | 1.15 | 90688 | 4.35330252 | CS |
156 | -75.28 | -98.4052287582 | 76.5 | 87.6 | 1.15 | 437301 | 30.61203363 | CS |
260 | -29.98 | -96.0897435897 | 31.2 | 138.7875 | 1.15 | 777992 | 64.40686034 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions